A cyclic peptide analogue of the loop III region of platelet-derived growth factor-BB is a synthetic antigen for the native protein

Journal of Peptide Research

Volumn 53, Issue 1, 1999, Pages 68-74

  Patel, Greeta ^a,b   Husman, W ^a   Jehanli, A M ^a   Deadman, J J ^a   Green, D ^a   Kakkar, V V ^a   Brennand, D M ^a  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b Peptide Therapeutics Ltd   (United Kingdom)

Author keywords

Cyclic peptide; Platelet derived growth factor; Solid phase synthesis; Synthetic antigen

Indexed keywords

ANTIGEN; CARRIER PROTEIN; CYCLOPEPTIDE; CYSTEINE; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY TITER; ARTICLE; BETA CHAIN; CIRCULAR DICHROISM; CONJUGATION; CROSS REACTION; CYCLIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; IMMUNOCHEMISTRY; MASS SPECTROMETRY; PEPTIDE SYNTHESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN TARGETING; STRUCTURE ANALYSIS; VACCINE PRODUCTION;

EID: 0032989894     PISSN: 1397002X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3011.1999.tb01618.x     Document Type: Article

References (31)

1. 1. Heldin, C.-H. & Westermark, B. (1990) Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul. 1, 555-566.
2. 2. Ross, R. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809.
3. 3. Claesson-Welsh, L. (1994) Platelet-derived growth factor receptor signals. J. Biol. Chem. 269, 32023-32026.
4. 4. Heldin, C.-H. (1995) Dimerization of cell surface receptors in signal transduction. Cell 80, 213-223.
5. 5. Ferns, G.A.A., Raines, E.W., Sprugel, K.H., Motani, A.S., Reidy, M.A. & Ross, R. (1991) Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253, 1129-1132.
6. 6. Engström, U., Engström, A., Ernlund, A., Westermark, B. & Heldin, C.-H. (1992) Identification of a peptide antagonist for platelet-derived growth factor. J. Biol. Chem. 267, 16581-16587.
7. 7. Oefner, C., D'Arcy, A.D., Winkler, F.K., Eggimann, B. & Hosang, M. (1992) Crystal structure of human platelet-derived growth factor BB. EMBO J. 11, 3921-3926.
8. 8. Giese, N., LaRochelle, W.J., May-Siroff, M., Robbins, K.C. & Aaronson, S.A. (1990) A small v-sis/platelet-derived growth factor (PDGF) B-protein domain in which subtle conformational changes abrogate PDGF receptor interaction and transforming activity. Mol. Cell. Biol 10, 5496-5501.
9. 9. Burgen, A.S.V., Roberts, G.C.K. & Tute, M.S.eds. (1986) Interaction Energies in Molecular Graphics and Drug Design, Elsevier Science, B.V., New York, pp. 75-113.
10. 10. Hinds, M.G., Welsh, J.H. & Brennand, D.M. et al. (1991) Synthesis, conformational, properties, and antibody recognition of peptides containing beta-turn mimetics based on alpha-alkylproline derivative. J. Med. Chem. 34, 1777-1789.
11. 11. Richards, N.G.J., Hinds, M.G., Brennand, D.M., Glennie, M.J., Welsh, J.M. & Robinson, J.A. (1990) Probing the role of proline as a recognition element in peptide antigens. Biochem. Pharmacol. 40, 119-123.
12. 12. Arnon, R., Maron, E., Sela, M. & Anfinson, C.B. (1971) Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. Proc. Natl. Acad. Sci. USA. 68, 1450-1455.
13. 13. Muller, S., Plaué, S., Samama, J.P., Valette, M., Briand, J.P. & Van Regenmortel, M.H.V. (1990) Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus haemagglutinin. Vaccine 8, 308-314.
14. 14. Christodoulides, M., McGuiness, B.T. & Heckels, J.E. (1993) Immunization with synthetic peptides containing epitopes of the class 1 outer-membrane protein of Neisseria meningitidis: Production of bactericidal antibodies on immunization with a cyclic peptide. J. Gen. Microbiol. 139, 1729-1738.
15. 15. Seligman, S.J., Binley, J.M., Gorny, M.K., Burton, D.R., Zolla-Pazner, S. & Sokalowski, K.A. (1996) Characterization by serial deletion competition ELISAs of HIV-1, V3 loop epitopes recognized by monoclonal antibodies. Mol. Immunol. 33, 737-745.
16. 16. Conley, A.J., Conard, P. & Bondy, S. et al. (1994) Immunogenicity of synthetic HIV-1 gp120, V3-loop peptide-conjugate immunogens. Vaccine 12, 445-451.
17. 17. Hoogerhout, P., Donders, E.M.L.M. & Van Gaans ven Den Brink, J.A.M. et al. (1995) Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis. Infect. Immun. 63, 3473-3478.
18. 18. Van der Werf, S., Briand, J.P., Plaué, S., Burckard, J., Girard, M. & Van Regenmortel, M.H.V. (1994) Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies. Res. Virol. 145, 349-359.
19. 19. Joisson, C., Kuster, F., Plaué, S. & Van Regenmortel, M.H.V. (1993) Antigenic analysis of bean pod mottle virus using linear and cyclized synthetic peptides. Arch. Virol. 128, 299-317.
20. 20. Atherton, E. & Sheppard, R.C. (1989) Solid Phase Peptide Synthesis. A Practical Approach Series, IRL Press, Oxford.
21. 21. Rovero, P., Quartara, L. & Fabbri, G. (1991) Synthesis of cyclic peptides on solid support. Tetrahedron Lett. 32, 2639-2642.
22. 21. Kates, S.A., Sole, N.A., Johnson, C.R., Hudson, D., Barany, G. & Albericio, F. (1993) A novel, convenient, three-dimensional orthogonal strategy for solid-phase synthesis of cyclic peptides. Tetrahedron Lett. 34, 1549-1552.
23. 23. Spatola, A.F., Darlak, K. & Romanovskis, P. (1996) An approach to cyclic peptide libraries: Reducing epimerization in medium sized rings during solid phase synthesis. Tetrahedron Lett. 37, 591-594.
24. 24. Fischer, P.M., Retson, K.V., Tyler, M.I. & Howden, M.E.H. (1992) Application of arylsulphonyl side-chain protected arginines in solid-phase peptide synthesis based on 9-fluorenylmethoxycarbonyl amino protecting strategy. Int. J. Peptide Protein Res. 40, 19-24.
25. 25. Gudgeon, A.M., Patel, G., Hermon-Taylor, J., Hurley, P., Bowyer, R.C. & Jehanli, A.M.T. (1991) Detection of human pancreatic prophospholipase A2 activation using an immunoassay for the free activation peptide DSGISPR. Ann. Clin. Biochem. 28, 497-503.
26. 26. Bowyer, R.C., Jehanli, A.M.T., Patel, G. & Hermon-Taylor, J. (1991) Development of enzyme-linked immunosorbent assay for free human pro-colipase activation peptide (APGPR). Clinica Chimica Acta 200, 137-152.
27. 27. Brennand, D.M., Danson, M.J. & Hough, D.W. (1986) A comparison of ELISA screening methods for the production of monoclonal antibodies against soluble protein antigens. J. Immunol. Methods 93, 9-14.
28. 28. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
29. 29. Carpino, L.A., El-Faham, A., Minor, C. & Albericio, F.J. (1994) Advantageous applications of azabenzotriazole (triazolopyridine)-based coupling reagents to solid-phase peptide synthesis. J. Chem. Soc. Chem. Commun. 2, 201-203.
30. 30. McMurray, J.S., Lewis, C.A. & Obeyesekere, N.U. (1994) Influence of solid support, solvent and coupling reagent on the head-to-tail cyclization of resin-bound peptides. Pept. Res. 7, 195-206.
31. 31. Brennand, D.M., Dennehy, U. & Ellis, V. et al. (1997) Identification of a cyclic peptide inhibitor of platelet-derived growth factor-BB receptor-binding and mitogen-induced DNA synthesis in human fibroblasts. FEBS Lett. 413, 70-74.